Published in Lancet on November 21, 1987
In situ imaging of metals in cells and tissues. Chem Rev (2009) 2.03
Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics (2007) 1.55
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics. BMC Neurol (2016) 1.38
Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med (2014) 1.29
Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal (2014) 1.29
Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J Biol Chem (2011) 1.19
Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS One (2007) 1.18
Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther (2011) 1.16
Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One (2012) 1.13
Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One (2009) 1.13
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci (2015) 1.07
Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis (2008) 1.07
Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol (2005) 1.03
Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol Life Sci (2013) 1.02
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int (2014) 1.00
Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem J (1992) 0.99
Iron and neurodegeneration: from cellular homeostasis to disease. Oxid Med Cell Longev (2012) 0.97
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol (2015) 0.97
Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol (2012) 0.95
Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. Front Aging Neurosci (2013) 0.95
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Mapping brain metals to evaluate therapies for neurodegenerative disease. CNS Neurosci Ther (2010) 0.91
Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. Antioxid Redox Signal (2016) 0.89
The aetiology of idiopathic Parkinson's disease. Mol Pathol (2001) 0.88
Rare variants in β-Amyloid precursor protein (APP) and Parkinson's disease. Eur J Hum Genet (2015) 0.88
Vulnerability of welders to manganese exposure--a neuroimaging study. Neurotoxicology (2014) 0.88
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol (2001) 0.87
Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J Neural Transm (Vienna) (2006) 0.87
Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 Inflammasome. Cell Rep (2015) 0.85
Clues to the mechanism underlying dopamine cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 0.85
Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease. Mol Neurodegener (2014) 0.83
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna) (2010) 0.83
Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. Hum Brain Mapp (2016) 0.83
Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents. Res Pharm Sci (2011) 0.82
Iron accumulation in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.82
Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. Neurobiol Dis (2013) 0.81
Neuroproteomics as a promising tool in Parkinson's disease research. J Neural Transm (Vienna) (2008) 0.79
Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J Neural Transm (Vienna) (2006) 0.79
Dual-pathway multi-echo sequence for simultaneous frequency and T2 mapping. J Magn Reson (2016) 0.78
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Front Aging Neurosci (2016) 0.76
Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss. BMC Neurosci (2013) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease. J Neurol Sci (2017) 0.76
Tollip, an early regulator of the acute inflammatory response in the substantia nigra. J Neuroinflammation (2016) 0.75
Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP(+) by Transporter-Independent Export of the Intermediate MPDP(.). Antioxid Redox Signal (2015) 0.75
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages? PLoS One (2016) 0.75
Pallidonigroluysian degeneration with iron deposition: a study of three autopsy cases. Acta Neuropathol (1993) 0.75
Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches. Neuroradiology (2017) 0.75
Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice. J Neural Transm (Vienna) (2005) 0.75
Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biol (2017) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Servo action in the human thumb. J Physiol (1976) 4.93
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Servo action in human voluntary movement. Nature (1972) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36